Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients
Status:
Completed
Trial end date:
2017-02-03
Target enrollment:
Participant gender:
Summary
This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and
pharmacodynamics of single intravenous and subcutaneous doses of CFZ533 in healthy subjects
and intravenous doses in rheumatoid arthritis patients.